The vice-president of Robarts Research Institute is trying to put together a funding structure for Diabetogen, a biotechnology company, being spun off by the Institute.
He must assess the worth of the company, how the equity should be divided among its stakeholders, and how much of the business must be given up to first-round investors.
Publication Date: 05/09/2000
This is just an excerpt. This case is about Finance